tradingkey.logo
tradingkey.logo

Impact Biomedical Inc

IBO
View Detailed Chart
0.544USD
-0.021-3.70%
Close 03/30, 16:00ETQuotes delayed by 15 min
6.25MMarket Cap
LossP/E TTM

Impact Biomedical Inc

0.544
-0.021-3.70%
Intraday
1m
30m
1h
D
W
M
D

Today

-3.70%

5 Days

-30.28%

1 Month

+24.93%

6 Months

-17.32%

Year to Date

+7.68%

1 Year

-64.22%

View Detailed Chart

Key Insights

Impact Biomedical Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 217 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Impact Biomedical Inc's Score

Industry at a Glance

Industry Ranking
217 / 391
Overall Ranking
456 / 4542
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Impact Biomedical Inc Highlights

StrengthsRisks
Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.
Growing
The company is in a growing phase, with the latest annual income totaling USD 32.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 32.00K.
Undervalued
The company’s latest PE is -1.53, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 1.23M shares, increasing 31.56% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 814.88K shares of this stock.

Analyst Rating

Based on 0 analysts
--
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Impact Biomedical Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Impact Biomedical Inc Info

Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.
Ticker SymbolIBO
CompanyImpact Biomedical Inc
CEOHeuszel (Frank D)
Websitehttps://www.impactbiomedinc.com/
KeyAI